Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Lymphoma, Non-Hodgkin 2Multiple Myeloma 1Lymphoma, Follicular 1Leukemia, Lymphoid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1

Interventions

Dexamethasone 307Bortezomib 161Lenalidomide 130pomalidomide 112daratumumab 94carfilzomib 69Calcium Dobesilate 41Cyclophosphamide 40belantamab mafodotin 31elotuzumab 30fludarabine 27ixazomib 23isatuximab 21Melphalan 21venetoclax 18selinexor 17talquetamab 15Prednisone 15plerixafor 14Panobinostat 14Granulocyte Colony-Stimulating Factor 14Injections 12idecabtagene vicleucel 11Zoledronic Acid 11Thalidomide 11Azacitidine 11pembrolizumab 10tocilizumab 9nirogacestat 9liposomal doxorubicin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Multiple Myeloma × lucatumumab × Clear all
NCT00231166 2018-10-11

Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma

Novartis

Phase 1 Completed
33 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡